Stay updated with breaking news from Bart De Strooper. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts hailed full data Wednesday showing a new drug can slow cognitive decline in Alzheimer's patients, but warned improvements were comparatively small and the treatment can have serious side effects.
Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.
Experts hailed full data Wednesday showing a new drug can slow cognitive decline in Alzheimer's patients, but warned improvements were comparatively small and the treatment can have serious side effects.
The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with
Experts have hailed the lecanemab as 'beginning of the end' for Alzheimer's after the drug was found to slow cognitive decline by more than a quarter in clinical trials in America, Europe and Asia.